Chemical modification of epibatidine causes a switch from agonist to antagonist and modifies its selectivity for neuronal nicotinic acetylcholine receptors

Chemistry and Biology

Volumn 7, Issue 7, 2000, Pages 545-555

  Spang, Jörg E ^a   Bertrand, Sonia ^b   Westera, Gerrit ^a   Patt, Jörg T ^a   Schubiger, P August ^a   Bertrand, Daniel ^b  

^a ETH Zurich   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Acetylcholine receptors; Epibatidine analogues; nAChR; Neuronal nicotinic receptors

Indexed keywords

ANIMALIA; ANURA; DENDROBATIDAE;

EID: 0033925760     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(00)00138-1     Document Type: Article

References (65)

1. Daly J.W. Alkaloids from frog skins: selective probes for ion channels and nicotinic receptors. Braz. J. Med. Biol. Res. 28:1995;1033-1042.
2. Daly J.W. The chemistry of poisons in amphibian skin. Proc. Natl Acad. Sci. USA. 92:1995;9-13.
3. Daly J.W. Thirty years of discovering arthropod alkaloids in amphibian skin. J. Nat. Prod. 61:1998;162-172.
4. Brioni J.D., Decker M.W., Sullivan J.P., Arneric S.P. The pharmacology of (-)-nicotine and novel cholinergic channel modulators. Adv. Pharmacol. 37:1997;153-214.
5. Sullivan J.P., Bannon A.W. Epibatidine: pharmacological properties of a novel nicotinic acetylcholine receptor agonist and analgesic agent. CNS Drug Rev. 2:1996;21-39.
6. Bai D., Xu R., Zhu X. Epibatidine. Drugs of the Future. 22:1997;1210-1220.
7. Broka C.A. Synthetic approaches to epibatidine. Med. Chem. Res. 4:1994;449-460.
8. Dehmlow E.V. Epibatidine competition: synthetic work on a novel natural analgetic. J. Prakt. Chem./Chem.-Ztg. 337:1995;167-174.
9. Badio B., Garraffo M.H., Spande T.F., Daly J.W. Epibatidine:d and definition as a potent analgesic and nicotinic agonist. Med. Chem. Res. 4:1994;440-448.
10. Badio B., Garraffo H.M., Plummer C.V., Padgett W.L., Daly J.W. Synthesis and nicotinic activity of epiboxidine: an isoxazole analogue of epibatidine. Eur. J. Pharmacol. 321:1997;189-194.
11. 125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. J. Pharmacol. Exp. Ther. 282:1997;445-451.
12. Ding Y.-S., Caroll F.I.et al. Comparative studies of epibatidine derivatives [18F]NFEP and [18F]N-methyl-NFEP: kinetics, nicotinic effect and toxicity. Nucl. Med. Biol. 26:1999;139-148.
13. Gatley S.J., Volkow N.D.et al. In vitro and ex vivo autoradiographic studies of nicotinic acetylcholine receptors using [F-18]fluoronorchloroepibatidine in rodent and human brain. Nucl. Med. Biol. 25:1998;449-454.
14. Horti A.G., Dannals R.F. Synthesis and evaluation of N-[C-11]methylated analogues of epibatidine as tracers for positron emission tomographic studies of nicotinic acetylcholine receptors. J. Med. Chem. 41:1998;4199-4206.
15. 123I]IPH: A radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors. Synapse. 26:1997;392-399.
16. Scheffel U., Taylor G.F., Kepler J.A., Carroll F.I., Kuhar M.J. In vivo labeling of neuronal nicotinic acetylcholine receptors with radiolabeled isomers of norchloroepibatidine. Neuroreport. 6:1995;2483-2488.
17. Seerden J.P.G., Tulp M.T.M., Scheeren H.W., Kruse C.G. Synthesis and structure-activity data of some new epibatidine analogues. Bioorg. Med. Chem. 6:1998;2103-2110.
18. Badio B., Daly J.W. Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. 45:1994;563-569.
19. Sullivan J.P., Arneric S.P.et al. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity α4 β2 nicotinic acetylcholine receptor ligand. Neuropharmacology. 35:1996;725-734.
20. Moulton B.A., Thinschimdt J.S., Quintana R., Meyer E.M., Papke R.L. The pharmacology of epibatidine and ABT-418 on putative subtypes of rat neuronal nicotinic receptors. Mol. Pharmacol. 1996;. in press.
21. Papke R.L., Fiebre C.M., de Moulton B.A., Thinschmidt J.S., Quintana R., Meyer E.M. Activation and inhibition of neuronal nAChRs by potential therapeutic agents. Soc. Neurosci. 21:1995;607. (contains no data).
22. Bertrand S., Patt J.T., Spang J.E., Westera G., Schubiger P.A., Bertrand D. Neuronal nAChRs stereoselective to non-natural epibatidine derivatives. FEBS Lett. 450:1999;273-279.
23. Badio B., Shi D., Garraffo H.M., Daly J.W. Antinociceptive effects of the alkaloid epibatidine: further studies on involvement of nicotinic receptors. Drug Dev. Res. 36:1995;46-59.
24. Spang J.E., Patt J.T.W., Bertrand S., Bertrand D., Westera G., Schubiger P.A. Synthesis and electrophysiological studies of a novel epibatidine analogue. J. Recept. Signal. Trans Res. 19:1999;521-531.
25. Bonhaus D.W., Wong E.H.F.et al. Characterization of the electrophysiological, biochemical and behavioral actions of epibatidine. J. Pharmacol. Exp. Ther. 272:1995;1199-1203.
26. Sullivan J.P., Arneric S.P.et al. (Racemic)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 271:1994;624-631.
27. Beers W.H., Reich E. Structure and activity of acethylcholine. Nature. 228:1970;917-922.
28. Sheridan R.P., Nilakantan R., Dixon J.S., Venkataraghavan R. The ensemble approach to distance geometry: application to the nicotinic pharmacophore. J. Med. Chem. 29:1986;899-906.
29. Glennon R.A., Herndon J.L., Dukat M. Epibatidine-aided studies toward definition of a nicotine receptor pharmacophore. Med. Chem. Res. 4:1994;461-473.
30. Alkondon M., Pereira E.F.R., Cortes W.S., Maelicke A., Albuquerque E.X. Choline is a selective agonist of α7 nicotnic acetylcholine receptors in the rat brain neurons. Eur. J. Neurosci. 9:1997;2734-2742.
31. Lippiello P.M., Bencherif M., Prince R.J. The role of desensitization in CNS nicotinic receptor function. Clarke P.B.S., Quik M., Adkofer F., Thurau K. Effects of Nicotine on Biological Systems II. 1994;79-86 Birkhauser Verlag, Boston.
32. Mandelzys A., De Koninck P., Cooper E. Agonist and toxin sensitivities of ACh-evoked currents on neurons expressing multiple nicotinic ACh receptor subunits. J. Neurophysiol. 74:1995;1212-1221.
33. Papke R.L., Bencherif M., Lippiello P. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the α7 subtype. Neurosci. Lett. 213:1996;201-204.
34. Patt J.T., Spang J.E., Westera G., Buck A., Schubiger P.A. Synthesis and in vivo studies of [C11]N-methylepibatidine: comparison of the stereoisomers. Nucl. Med. Biol. 26:1999;165-173.
35. Alkondon M., Albuquerque E.X. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. III. Agonist actions of the novel alkaloid epibatidine and analysis of type II current. J. Pharmacol. Exp. Ther. 274:1995;771-782.
36. Bertrand D., Bertrand S., Ballivet M. Pharmacological properties of the homomeric α7 receptor. Neurosci. Lett. 146:1992;87-90.
37. Gopalakrishnan M., Sullivan J.P.et al. Stable expression and pharmacological properties of the human α7 nicotinic acetylcholine receptor. Eur. J. Pharmacol. 290:1995;237-246.
38. Seguela P., Wadiche J., Dineley Miller K., Dani J.A., Patrick J.W. Molecular cloning, functional properties, and distribution of rat brain α7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. 13:1993;596-604.
39. Antonov S.M., Johnson J.W., Lukomskaya N.Y., Potapyeva N.N., Gmiro V.E., Magazanik L.G. Novel adamantane derivatives act as blockers of open ligand-gated channels and as anticonvulsants. Mol. Pharmacol. 47:1995;558-567.
40. Buisson B., Bertrand D. Open-channel blockers at the human α4β2 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53:1998;555-563.
41. Leonard R.J., Lester H.A.et al. Reverse pharmacology of the nicotinic acetylcholine receptor. Mapping the local anesthetic binding site. Ann. N.Y. Acad. Sci. 625:1991;588-599.
42. Revah F., Changeux J.P.et al. Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor. Nature. 353:1991;846-849.
43. Bertrand D., Changeux J.-P. Nicotinic receptor: an allosteric protein specialized for intercellular communication. Neurosciences. 7:1995;75-90.
44. Changeux J.P., Zoli M.et al. Brain nicotinic receptors: structure and regulation, role in learning and reinforcement. Brain Res. Rev. 26:1998;198-216.
45. Hucho F., Tsetlin V.I., Machold J. The emerging three-dimensional structure of a receptor. The nicotinic acetylcholine receptor. Eur. J. Biochem. 239:1996;539-557.
46. Unwin N. The nicotinic acetylcholine receptor of the Torpedo electric ray. J. Struct. Biol. 121:1998;181-190.
47. Glennon R.A., Dukat M. Nicotinic cholinergic receptor pharmacophore. Arneric S.P., Brioni J.D. Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities. 1999;271-284 Wiley-Liss, New York.
48. Tsigelny I., Sugiyama N., Sine S.M., Taylor P. A model of the nicotinic receptor extracellular domain based on sequence identity and residue location. Biophys. J. 73:1997;52-66.
49. Galzi J.L., Bertrand S., Corringer P.J., Changeux J.P., Bertrand D. Identification of calcium binding sites that regulate potentiation of a neuronal nicotinic acetylcholine receptor. EMBO J. 15:1996;5824-5832.
50. Buisson B., Bertrand D. Allosteric modulation of neuronal nicotinic acetylcholine receptors. J. Physiol. 92:1998;89-100.
51. Dennis M., Changeux J.-P.et al. Aminoacids of the Torpedo marmorata acetylcholine receptor alpha subunit labeled by a photoaffinity ligand for the acetylcholine receptor by photoaffinity labelling. Biochemistry. 27:1988;2346-2357.
52. Galzi J.L., Revah F., Black D., Goeldner M., Hirth C., Changeux J.P. Identification of a novel amino acid alpha-tyrosine 93 within the cholinergic ligands-binding sites of the acetylcholine receptor by photoaffinity labeling. Additional evidence for a three-loop model of the cholinergic ligands-binding sites. J. Biol. Chem. 265:1990;10 430-10 437.
53. Abramson S.N., Li Y., Culver P., Taylor P. An analog of lophotoxin reacts covalently with tyrosine 190 in the alpha-subunit of the nicotinic acetylcholine receptor. J. Biol. Chem. 264:1989;12 666-12 672.
54. Changeux J.P., Edelstein S.J. Allosteric receptors after 30 years. Neuron. 21:1998;959-980.
55. Edelstein S.J., Schaad O., Henry E., Bertrand D., Changeux J.P. A kinetic mechanism for nicotinic acetylcholine receptors based on multiple allosteric transitions. Biol. Cybern. 75:1996;361-379.
56. Edelstein S.J., Changeux J.P. Allosteric proteins after thirty years: the binding and state functions of the neuronal α7 nicotinic acetylcholine receptors. Experientia. 52:1996;1083-1090.
57. Monod J., Wyman J., Changeaux J.P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12:1965;88-118.
58. Rubin M.M., Changeux J.P. On the nature of allosteric transitions: implications of non-exclusive ligand binding. J. Mol. Biol. 21:1966;265-274.
59. Williams M., Sullivan J.P., Arneric S.P. Neuronal nicotinic acetylcholin receptors. Drug News Perspect. 7:1994;205-223.
60. Clayton S.C., Regan A.C. A total synthesis of (±)-epibatidine. Tetrahedron Lett. 34:1993;7493-7496.
61. Bai D., Xu R., Chu G., Zhu X. Synthesis of (±)-epibatidine and its analogues. J. Org. Chem. 61:1996;4600-4606.
62. Spang J.E., Patt J.T., Westera G., Schubiger P.A. Synthesis and [11C]-radiolabelling of dechloroepibatidine and 2PABH, two potential radioligands for studying the central nAChRs in vivo. J. Labelled Compd. Rad. 42:1999;761-771.
63. 11C]methyl-epibatidine via PET of small animals. Nucl. Med. Biol. 27:2000;. in press.
64. Bertrand D., Cooper E., Valera S. Electrophysiology of neuronal nicotinic receptors expressed in Xenopus oocytes, following nuclear injection of genes or cDNAs. Methods Neurosci. 4:1991;174-193.
65. Bertrand D., Buisson B., Krause R.M., Hu H.-Y., Bertrand S. Electrophysiology: a method to investigate the functional properties of ligand-gated channels. J. Recept. Signal. Tr. Res. 17:1997;227-242.